| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Center for Immunology, Department of Pathology and Immunology,
Division of Pulmonary and Critical Care Medicine,
Division of Rheumatology and Howard Hughes Medical Institute, Washington University School of Medicine, St. Louis, MO 63110; and
Department of Microbiology and Immunology and the Cancer Research Institute, University of California, San Francisco, CA 94143
In this study, we show that IFN-
or IFN-
reduce expression of H60 on 3'-methylcholanthrene (MCA) sarcomas from 129/Sv mice. As determined by flow cytometry using either NKG2D tetramers or NKG2D ligand-specific mAb, H60 was identified as the NKG2D ligand most frequently expressed on these sarcomas, and its expression was selectively down-regulated by either IFN- or IFN- in a manner that was dose- and time-dependent and reversible. Down-regulation occurred at the transcript level and was STAT1-dependent. It also had functional consequences. IFN--treated MCA sarcomas with high levels of H60 were resistant to killing by IL-2-activated NK cells. Resistance was not solely dependent on enhanced MHC class I expression but rather also required H60 down-regulation. IFN--treated tumor cells also displayed diminished capacity to down-regulate NKG2D on freshly isolated NK cells. Transplanted tumor cells reisolated from immunocompetent mice displayed reduced H60 expression and increased MHC class I expression compared with tumor cells that were either left unmanipulated or reisolated from mice treated with neutralizing IFN--specific mAb. This report thus represents the first demonstration that certain cytokines and specifically the IFNs regulate expression of specific NKG2D ligands on murine tumors. This process most likely helps to specify the type of immune effector cell populations that participate in host-protective antitumor responses.
This article has been cited by other articles:
|
|
 |
|
  Y.-O. Ahn, J.-C. Lee, M.-W. Sung, and D. S. Heo Presence of Membrane-Bound TGF-{beta}1 and Its Regulation by IL-2-Activated Immune Cell-Derived IFN-{gamma} in Head and Neck Squamous Cell Carcinoma Cell Lines J. Immunol., May 15, 2009; 182(10): 6114 - 6120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cerwenka New twist on the regulation of NKG2D ligand expression J. Exp. Med., February 16, 2009; 206(2): 265 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. N. Buhtoiarov, A. L. Rakhmilevich, L. L. Lanier, E. A. Ranheim, and P. M. Sondel Naive Mouse Macrophages Become Activated following Recognition of L5178Y Lymphoma Cells via Concurrent Ligation of CD40, NKG2D, and CD18 Molecules J. Immunol., February 15, 2009; 182(4): 1940 - 1953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Yadav, J. Ngolab, R. S.-H. Lim, S. Krishnamurthy, and J. D. Bui Cutting Edge: Down-Regulation of MHC Class I-Related Chain A on Tumor Cells by IFN-{gamma}-Induced MicroRNA J. Immunol., January 1, 2009; 182(1): 39 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Liu, L. Ye, Y. Bai, H. Mojidi, N. E. Simister, and X. Zhu Activation of the JAK/STAT-1 Signaling Pathway by IFN-{gamma} Can Down-Regulate Functional Expression of the MHC Class I-Related Neonatal Fc Receptor for IgG J. Immunol., July 1, 2008; 181(1): 449 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Galazka, A. Jurewicz, W. Orlowski, M. Stasiolek, C. F. Brosnan, C. S. Raine, and K. Selmaj EAE Tolerance Induction with Hsp70-Peptide Complexes Depends on H60 and NKG2D Activity J. Immunol., October 1, 2007; 179(7): 4503 - 4512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Basu, T. L. Tinder, J. M. Bradley, T. Tu, C. L. Hattrup, B. A. Pockaj, and P. Mukherjee Cyclooxygenase-2 Inhibitor Enhances the Efficacy of a Breast Cancer Vaccine: Role of IDO J. Immunol., August 15, 2006; 177(4): 2391 - 2402. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
